Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 2-year efficacy and safety results from the GATHER2 phase 3 trial

Macular Diseases

Intravitreal Aflibercept 8 mg in Neovascular Age-related Macular Degeneration: 96-Week Results from the Randomized Phase 3 PULSAR Trial

Ophthalmology

Korobelnik JF, Lanzetta P, Leal S, Holz FG, Clark WL, Eichenbaum D, Iida T, Sun X, Berliner AJ, Schulze A, Zhao M, Schmelter T, Schmidt-Ott U, Zhang X, Morgan-Warren P, Hasanbasic Z, Vitti R, Chu KW, Reed K, Bhore R, Cheng Y, Bai Z, Hirshberg B, Yancopoulos GD, Wong TY, PULSAR investigators

doi: 10.1016/j.ophtha.2025.08.022

Macular Diseases

Long-Term Efficacy and Safety of CT-P42 in Patients with Diabetic Macular Edema: 52-Week Results from a Phase 3 Randomized Clinical Trial

Ophthalmol Ther

Brown DM, Wolf S, Veselovsky M, Veith M, Papp A, Mange S, Mondal LK, Romanczak D, Janco L, Chauhan R, Romanowska-Dixon B, Eremina A, Dusova J, Sagong M, Kim S, Bae Y, Kim S, Bae Y, Son D, Kang H, Choi S, Stanga PE

doi: 10.1007/s40123-025-01197-w

Macular Diseases

Two-Year Switzerland Cohort Results from a Global Observational Study Investigating Proactive Dosing with Intravitreal Aflibercept 2 mg in Neovascular Age-Related Macular Degeneration

J Clin Med

Hatz K, Ambresin A, Schmid M, Prünte C, Barthelmes D, Machewitz T, Allmeier H, Somfai GM, XTEND Study Group

doi: 10.3390/jcm14072370

Macular Diseases

Ten-Year Incidence, Risk Factors and Progression Rate of Macular Atrophy in Neovascular Age-Related Macular Degeneration

Clin Exp Ophthalmol

Romano F, Casaluci M, Valastro A, Airaldi M, Milella P, Pozzo Giuffrida F, Cozzi E, Aretti A, Teo KY, Cheung CMG, Nassisi M, Viola F, Staurenghi G, Invernizzi A

doi: 10.1111/ceo.14608

Macular DiseasesRetinal Diseases

Impact of retinal thickness fluctuations with ranibizumab versus aflibercept in neovascular age-related macular degeneration (SALT): 12-month results from a multicentre, randomised, phase IV trial

Br J Ophthalmol

Agostini HT, Silva R, Holz FG, Larsen M, Altay L, Souied EH, Quiering C, Rose U, Liakopoulos S, SALT study group

doi: 10.1136/bjo-2024-326526

LensesMacular Diseases

Safety and efficacy of an extended macular vision intraocular lens (IOL) for age-related macular degeneration (AMD) in real-world settings

BMC Ophthalmol

Hengerer FH, Stanzel B, Hoyos-Chacon J, Suarez M, Beckers S, Busatto P, Badalà F

doi: 10.1186/s12886-025-04515-9

Macular Diseases

TALON Phase IIIb Study: 32 Week Primary Results of Brolucizumab Using Treat and Extend for Neovascular Age Related Macular Degeneration

Ophthalmol Retina

Regillo C, Kaiser PK, Kertes PJ, Gillies M, Maio-Twofoot T, D'Souza D, Guenther S, Lawrence D, Holz FG

doi: 10.1016/j.oret.2025.05.030

Macular Diseases

Real-World Experience with Intravitreal Pegcetacoplan for the Treatment of Geographic Atrophy in Age-Related Macular Degeneration

Am J Ophthalmol

Shen M, Berni A, Liu J, Hiya F, Herrera G, El-Mulki OS, Beqiri S, Cheng Y, Kastner J, Trivizki O, Kumar S, Zhang Y, Le VH, O'Brien RC, Nicola MD, Yehoshua Z, Dubovy SR, Wang RK, Gregori G, Rosenfeld PJ

doi: 10.1016/j.ajo.2025.09.006

Macular Diseases

Vision-related quality of life impact of age-related macular degeneration in older adults aged 60-100 years: a cross-sectional study

Br J Ophthalmol

Vu TA, Fenwick EK, Man REK, Thakur S, Tan ACS, Cheung CMG, Gupta P, Lamoureux EL

doi: 10.1136/bjo-2024-325713

Related content

Intravitreal Aflibercept 8 mg in Neovascular Age-related Macular Degeneration: 96-Week Results from the Randomized Phase 3 PULSAR Trial

Long-Term Efficacy and Safety of CT-P42 in Patients with Diabetic Macular Edema: 52-Week Results from a Phase 3 Randomized Clinical Trial

Two-Year Switzerland Cohort Results from a Global Observational Study Investigating Proactive Dosing with Intravitreal Aflibercept 2 mg in Neovascular Age-Related Macular Degeneration

Ten-Year Incidence, Risk Factors and Progression Rate of Macular Atrophy in Neovascular Age-Related Macular Degeneration

Impact of retinal thickness fluctuations with ranibizumab versus aflibercept in neovascular age-related macular degeneration (SALT): 12-month results from a multicentre, randomised, phase IV trial

Safety and efficacy of an extended macular vision intraocular lens (IOL) for age-related macular degeneration (AMD) in real-world settings

TALON Phase IIIb Study: 32 Week Primary Results of Brolucizumab Using Treat and Extend for Neovascular Age Related Macular Degeneration

Real-World Experience with Intravitreal Pegcetacoplan for the Treatment of Geographic Atrophy in Age-Related Macular Degeneration

Vision-related quality of life impact of age-related macular degeneration in older adults aged 60-100 years: a cross-sectional study